Early trial termination results from "overwhelming" bleeding reduction with abelacimab compared to rivaroxaban in AF.

Published Date: 22 Sep 2023

USA: The novel factor XI/XIa inhibitor abelacimab, which is being tested in the AZALEA-TIMI 71 trial, was shown to reduce a composite of major and clinically.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot